nach oben

Supportive Care in Cancer

Erschienen in:

24.06.2022 | Editorial

Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)

verfasst von: Hartmut Link

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2022

Einloggen, um Zugang zu erhalten

Excerpt

Granulocyte colony-stimulating factor (G-CSF), a protein that stimulates the growth of new blood cells, was isolated from human cells by Malcolm Moore and Karl Welte in 1984 [1]. It formed the basis for filgrastim, one of the most important drugs in cancer therapy [2]. In the hierarchical development of hematopoiesis, G-CSF predominantly stimulates the myeloid cell series from committed progenitor cells to mature neutrophil granulocytes. There are several important effects of G-CSF: maintaining the viability of progenitor cells and their mature progeny, blocking apoptosis, stimulating cell division, determining lineage affiliation (granulocytes or macrophage monocytes), influencing the maturation process, and stimulating phagocytosis activity [3]. Natural G-CSF is O-glycosylated with a molecular weight of 19,000 Da. Derived from the amino acid sequence, molecular cloning of the cDNA and expression in Escherichia coli was successful [4]. G-CSF acts through a homodimeric G-CSF receptor (GCSFR) expressed on myeloid cells from myeloblasts to mature neutrophils. It transduces the signals that trigger the effects described [5]. The GCSFR occurs at a relatively low density of 700–1500 per cell on the cell surface and has a high affinity for G-CSF. A low occupancy at receptors is sufficient to obtain the maximal biological response. …

Welte K, Platzer E, Lu L, Gabrilove JL, Levi E, Mertelsmann R et al (1985) Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci 82(5):1526–1530. https://doi.org/10.1073/pnas.82.5.1526CrossRefPubMedPubMedCentral

Welte K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): The first 10 years. Blood 88(6):1907–1929CrossRef

Metcalf D (2013) The colony-stimulating factors and cancer. Cancer Immunol Res 1(6):351–356. https://doi.org/10.1158/2326-6066.cir-13-0151CrossRefPubMedPubMedCentral

Souza LM, Boone TC, Gabrilove J, Lai PH, Zsebo KM, Murdock DC et al (1986) Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232(4746):61–65. https://doi.org/10.1126/science.2420009CrossRefPubMed

Demetri GD, Griffin JD (1991) Granulocyte colony-stimulating factor and its receptor. Blood 78(11):2791–2808. https://doi.org/10.1182/blood.v78.11.2791.2791CrossRefPubMed

Bajrami B, Zhu H, Kwak HJ, Mondal S, Hou Q, Geng G et al (2016) G-CSF maintains controlled neutrophil mobilization during acute inflammation by negatively regulating CXCR2 signaling. J Exp Med 213(10):1999–2018. https://doi.org/10.1084/jem.20160393CrossRefPubMedPubMedCentral

Lieschke GJ, Grail D, Hodgson G, Metcalf D, Stanley E, Cheers C et al (1994) Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84:1737–1746CrossRef

Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA et al (1994) Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 91:5592–5596CrossRef

Metcalf D (2010) The colony-stimulating factors and cancer. Nat Rev Cancer 10(6):425–434. https://doi.org/10.1038/nrc2843CrossRefPubMedPubMedCentral

10.

Ratiograstim Epar Product Information (2021) Filgrastim. European Medicines Agency, London

11.

Molineux G (2003) Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anti-Cancer Drugs 14(4):259–264CrossRef

12.

Buchner A, Lammerich A, Abdolzade-Bavil A, Muller U, Bias P (2014) Lipegfilgrastim: pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers. Curr Med Res Opin 30(12):2523–2533. https://doi.org/10.1185/03007995.2014.962131CrossRefPubMed

13.

Lévesque J-P, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ (2003) Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Investig 111(2):187–196. https://doi.org/10.1172/jci15994CrossRefPubMedPubMedCentral

14.

Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD (1988) Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1(8596):1194–1198. https://doi.org/10.1016/s0140-6736(88)92012-0CrossRefPubMed

15.

Lapidot T, Petit I (2002) Current understanding of stem cell mobilization. Exp Hematol 30(9):973–981. https://doi.org/10.1016/s0301-472x(02)00883-4CrossRefPubMed

16.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR et al (2012) Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 367(16):1487–1496. https://doi.org/10.1056/nejmoa1203517CrossRefPubMed

17.

Link H, Arseniev L, Bähre O, Kadar J, Diedrich H, Poliwoda H (1996) Transplantation of allogeneic CD34+ blood cells. Blood 87(11):4903–4909

18.

Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A et al (1996) Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 347:353–357CrossRef

19.

Pahnke S, Egeland T, Halter J, Hägglund H, Shaw BE, Woolfrey AE et al (2019) Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation. Bone Marrow Transplant 54(6):858–866. https://doi.org/10.1038/s41409-018-0350-yCrossRefPubMed

20.

Hübel K (2019) Mobilization and Collection of HSC. In: Carreras E, Dufour C, Mohty M, Kröger N (eds) The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. Springer, Cham (CH), pp 117–122CrossRef

21.

Trivedi M, Martinez S, Corringham S, Medley K, Ball ED (2009) Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant 43(12):895–908. https://doi.org/10.1038/bmt.2009.75CrossRefPubMed

22.

Klein E-M, Sauer S, Klein S, Tichy D, Benner A, Bertsch U et al (2021) Antibiotic prophylaxis or granulocyte-colony stimulating factor support in multiple myeloma patients undergoing autologous stem cell transplantation. Cancers 13(14):3439. https://doi.org/10.3390/cancers13143439CrossRefPubMedPubMedCentral

23.

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33(28):3199–3212. https://doi.org/10.1200/JCO.2015.62.3488CrossRefPubMed

24.

Gupta AK, Meena JP, Haldar P, Tanwar P, Seth R (2021) Impact of G-CSF administration post-allogeneic hematopoietic stem-cell transplantation on outcomes: a systematic review and meta-analysis. Am J Blood Res 11(5):544–563PubMedPubMedCentral

25.

Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414–1422CrossRef

26.

Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325(3):164–170. https://doi.org/10.1056/NEJM199107183250305CrossRefPubMed

27.

Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM et al (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24(10):2475–2484. https://doi.org/10.1093/annonc/mdt226CrossRefPubMedPubMedCentral

28.

Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z (2015) Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer 23(2):525–545. https://doi.org/10.1007/s00520-014-2457-zCrossRefPubMed

29.

Lyman GH, Yau L, Nakov R, Krendyukov A (2018) Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support. Ann Oncol 29(9):1903–1910. https://doi.org/10.1093/annonc/mdy311CrossRefPubMed

30.

Lyman GH, Dale DC, Wolff DA, Culakova E, Poniewierski MS, Kuderer NM et al (2010) Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 28(17):2914–2924. https://doi.org/10.1200/jco.2009.25.8723CrossRefPubMed

31.

Griffiths EA (2021) NCCN Guidelines Version 3.2021, Hematopoietic growth factors. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

32.

Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review. Crit Rev Oncol Hematol 90(3):190–199. https://doi.org/10.1016/j.critrevonc.2013.12.006CrossRefPubMed

33.

Aapro MS, Bohlius J, Cameron DA, Dal LL, Donnelly JP, Kearney N et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32CrossRef

34.

Link H, Kerkmann M, Holtmann L, Ortner P (2019) Working Groups Supportive C, Medical Oncology within the German Cancer S. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey. Support Care Cancer 27(4):1459–1469. https://doi.org/10.1007/s00520-018-4481-xCrossRefPubMed

35.

Link H, Nietsch J, Kerkmann M, Ortner P (2016) Supportive Care Group of the German Cancer S. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy-a representative sample survey in Germany. Support Care Cancer 24(1):367–376. https://doi.org/10.1007/s00520-015-2779-5CrossRefPubMed

36.

Nielson CM, Bylsma LC, Fryzek JP, Saad HA, Crawford J (2021) Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. The Oncologist 26(9):e1609–e1e18. https://doi.org/10.1002/onco.13822CrossRefPubMedPubMedCentral

37.

Pettengell R, Schwenkglenks M, Bosly A (2008) Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 87(5):429–430. https://doi.org/10.1007/s00277-008-0447-2CrossRefPubMedPubMedCentral

38.

Gray R, Bradley R, Braybrooke J, Liu Z, Peto R, Davies L et al (2019) Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet 393(10179):1440–1452. https://doi.org/10.1016/S0140-6736(18)33137-4CrossRef

39.

Pfister C, Gravis G, Flechon A, Chevreau CM, Mahammedi H, Laguerre B et al (2021) 652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial. Ann Oncol 32:S678. https://doi.org/10.1016/j.annonc.2021.08.048CrossRef

40.

Lyman GH, Yau L, Nakov R, Krendyukov A (2017a) a systematic literature review of overall survival and delivered dose intensity in cancer patients receiving chemotherapy and G-CSF in randomized control trials. Blood 130(Suppl 1):3424

41.

ASCO's 2021 top five list in oncology (2021). https://www.asco.org/news-initiatives/current-initiatives/cancer-care-initiatives/value-cancer-care/choosing-wisely. Accessed 20.12.2021

42.

Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E et al (2018) A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer 26(1):7–20. https://doi.org/10.1007/s00520-017-3854-xCrossRefPubMed

43.

Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M et al (2000) Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 18(4):780–787CrossRef

44.

Link H, Wandt H, Schönrock-Nabulsi P, Ehninger G, Franke A, Gäckle R et al (1996b) G-CSF (Lenograstim) after chemotherapy for acute myeloid leukemia: A placebo controlled trial. Blood 88(10, Suppl. 1):666a

45.

Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T et al (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323(13):871–877. https://doi.org/10.1056/NEJM199009273231304CrossRefPubMed

46.

Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al (1995) A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 332(25):1678–1683. https://doi.org/10.1056/NEJM199506223322504CrossRefPubMed

47.

Gurion R, Belnik-Plitman Y, Gafter-Gvili A, Paul M, Vidal L, Ben-Bassat I et al (2012) Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008238.pub3

48.

Desai PM, Brown J, Gill S, Solh MM, Akard LP, Hsu JW et al (2021) Open-label phase II prospective, randomized, controlled study of romyelocel-L Myeloid progenitor cells to reduce infection during induction chemotherapy for acute myeloid leukemia. J Clin Oncol 39(29):3261–3272. https://doi.org/10.1200/jco.20.01739CrossRefPubMed

49.

Feng X, Lan H, Ruan Y, Li C (2018) Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis. Hematology 23(9):581–589. https://doi.org/10.1080/10245332.2018.1446811CrossRefPubMed

50.

Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J et al (2013) Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 31(27):3360–3368. https://doi.org/10.1200/jco.2012.47.4874CrossRefPubMed

51.

Tichelli A, De Latour RP, Passweg J, Knol-Bout C, Socié G, Marsh J et al (2020) Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a severe aplastic anemia working party. Haematologica 105(5):1223–1231. https://doi.org/10.3324/haematol.2019.222562CrossRefPubMedPubMedCentral

52.

Townsley DM, Scheinberg P, Winkler T, Desmond R, Dumitriu B, Rios O et al (2017) Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med 376(16):1540–1550. https://doi.org/10.1056/NEJMoa1613878CrossRefPubMedPubMedCentral

53.

Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A et al (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol 172(2):187–207. https://doi.org/10.1111/bjh.13853CrossRefPubMed

54.

DiCarlo AL, Horta ZP, Aldrich JT, Jakubowski AA, Skinner WK, Case CM Jr (2019) Use of growth factors and other cytokines for treatment of injuries during a radiation public health emergency. Radiat Res 192(1):99–120. https://doi.org/10.1667/rr15363.1CrossRefPubMedPubMedCentral

55.

Farese AM, MacVittie TJ (2015) Filgrastim for the treatment of hematopoietic acute radiation syndrome. Drugs Today (Barc) 51(9):537–548. https://doi.org/10.1358/dot.2015.51.9.2386730CrossRef

56.

Hankey KG, Farese AM, Blaauw EC, Gibbs AM, Smith CP, Katz BP et al (2015) Pegfilgrastim Improves survival of lethally irradiated nonhuman primates. Radiat Res 183(6):643–655. https://doi.org/10.1667/rr13940.1CrossRefPubMed

57.

Yarza R, Bover M, Paredes D, López-López F, Jara-Casas D, Castelo-Loureiro A et al (2020) SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. Eur J Cancer 135:242–250. https://doi.org/10.1016/j.ejca.2020.06.001CrossRefPubMedPubMedCentral

58.

COVID-19 Patient Care Information - Cancer Treatment & Supportive Care (2021). https://www.asco.org/covid-resources/patient-care-info/cancer-treatment-supportive-care. Accessed 01/31/2022 2021

59.

Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P et al (2020) Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. J Natl Compr Canc Netw 1-4. https://doi.org/10.6004/jnccn.2020.7610

60.

Aapro M, Lyman GH, Bokemeyer C, Rapoport BL, Mathieson N, Koptelova N et al (2021) Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open 6(1). https://doi.org/10.1016/j.esmoop.2020.100038

61.

Zhang AW, Morjaria S, Kaltsas A, Hohl TM, Parameswaran R, Patel D et al (2021) The Effect of Neutropenia and Filgrastim (G-CSF) in Cancer Patients With COVID-19 Infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America: ciab534. https://doi.org/10.1093/cid/ciab534

62.

Sereno M, Jimenez-Gordo AM, Baena-Espinar J, Aguado C, Mielgo X, Pertejo A et al (2021) A multicenter analysis of the outcome of cancer patients with neutropenia and COVID-19 optionally treated with Granulocyte-Colony Stimulating Factor (G-CSF): A comparative analysis. Cancers 13(16). https://doi.org/10.3390/cancers13164205

63.

Lasagna A, Muzzana M, Pedrazzoli P (2021) Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research. Immunotherapy 13(17):1369–1372. https://doi.org/10.2217/imt-2021-0219CrossRefPubMed

64.

Cooksley T, Font C, Scotte F, Escalante C, Johnson L, Anderson R et al (2021) Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer 29(2):1129–1138. https://doi.org/10.1007/s00520-020-05906-yCrossRefPubMed

65.

Weycker D, Hackett J, Edelsberg JS, Oster G, Glass AG (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40(3):402–407. https://doi.org/10.1345/aph.1G516CrossRefPubMed

66.

Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y et al (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in us clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 25(2):439–447. https://doi.org/10.1007/s00520-016-3421-xCrossRefPubMed

67.

Lyman GH, Allcott K, Garcia J, Stryker S, Li Y, Reiner MT et al (2017b) The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. Support Care Cancer 25(8):2619–2629. https://doi.org/10.1007/s00520-017-3703-yCrossRefPubMed

68.

Neulasta -Pegfilgrastim. European Medicines Agency; 2007

69.

NEULASTA® (pegfilgrastim) injection. Silver Spring, MD 2099: European Medicines Agency: U.S. Food and Drug Administration

70.

Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK (2014) Biosimilars: the science of extrapolation. Blood 124(22):3191–3196. https://doi.org/10.1182/blood-2014-06-583617CrossRefPubMed

71.

Biosimilars of filgrastim (2021). https://www.gabionline.net/biosimilars/general/Biosimilars-of-filgrastim. Accessed 20.12.2021 2021

72.

Pettengell R, Bias P, Mueller U, Lang N (2016) Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor. Support Care Cancer. 24(6):2677–2684. https://doi.org/10.1007/s00520-015-3057-2CrossRefPubMed

73.

Ghidini M, Indini A, Nigro O, Polito S, Rijavec E, Petrelli F et al (2021) Advances in the pharmacological management of neutropenia in solid tumors: the advent of biosimilars. Expert Opin Pharmacother 22(7):857–865. https://doi.org/10.1080/14656566.2021.1873950CrossRefPubMed

74.

Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, Kohler A et al (2021) Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Support Care Cancer 29(5):2519–2527. https://doi.org/10.1007/s00520-020-05711-7CrossRefPubMed

75.

Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C et al (2012) Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 30(16):1974–1979. https://doi.org/10.1200/JCO.2011.37.8364CrossRefPubMedPubMedCentral

76.

Kirshner JJ, McDonald MC, Kruter F, Guinigundo AS, Vanni L, Maxwell CL et al (2018) NOLAN: a randomized, phase 2 study to estimate the effect of prophylactic naproxen or loratadine vs no prophylactic treatment on bone pain in patients with early-stage breast cancer receiving chemotherapy and pegfilgrastim. Support Care Cancer 26(4):1323–1334. https://doi.org/10.1007/s00520-017-3959-2CrossRefPubMed

77.

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JF, Anson-Cartwright L et al (2017) Impact of granulocyte-colony stimulating factor on bleomycin-induced pneumonitis in chemotherapy-treated germ cell tumors. Clin genitourinary cancer. https://doi.org/10.1016/j.clgc.2017.08.012

78.

Laprise-Lachance M, Lemieux P, Grégoire JP (2019) Risk of pulmonary toxicity of bleomycin and filgrastim. Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners 25(7):1638–1644. https://doi.org/10.1177/1078155218804293CrossRef

79.

Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Iijima M et al (2022) Analysis of the safety of pegfilgrastim addition in bleomycin, etoposide, and cisplatin treatment patients with germ cell tumors. Front Oncol:11. https://doi.org/10.3389/fonc.2021.770067

80.

Andersen MD, Kamper P, d’Amore A, Clausen M, Bentzen H, d'Amore F (2019) The incidence of bleomycin induced lung toxicity is increased in Hodgkin lymphoma patients over 45 years exposed to granulocyte-colony stimulating growth factor. Leuk Lymphoma 60(4):927–933. https://doi.org/10.1080/10428194.2018.1515939CrossRefPubMed

81.

Lyman GH, Kuderer NM (2002) Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 62(Suppl 1):65–78CrossRef

82.

Lapidari P, Vaz-Luis I, Di Meglio A (2021) Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review. Crit Rev Oncol Hematol. 157:103193. https://doi.org/10.1016/j.critrevonc.2020.103193CrossRefPubMed

83.

Vanderpuye-Orgle J, Sexton Ward A, Huber C, Kamson C, Jena AB (2016) Estimating the social value of G-CSF therapies in the United States. Am J Manag Care 22(10):e343–e3e9PubMed

84.

Bunn PA Jr, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C et al (1995) Chemoradiotherapy with or without granulocyte-macrophage colony- stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13(7):1632–1641CrossRef

85.

Sheikh H, Colaco R, Lorigan P, Blackhall F, Califano R, Ashcroft L et al (2011) Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung Cancer 74(1):75–79. https://doi.org/10.1016/j.lungcan.2011.01.020CrossRefPubMed

86.

Gomes F, Faivre-Finn C, Mistry H, Bezjak A, Pourel N, Fournel P et al (2021) Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. Lung Cancer 153:165–170. https://doi.org/10.1016/j.lungcan.2021.01.025CrossRefPubMed

87.

Benna M, Guy J-B, Bosacki C, Jmour O, Ben Mrad M, Ogorodniitchouk O et al (2020) Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box? Br J Radiol 93(1109):20190147. https://doi.org/10.1259/bjr.20190147CrossRefPubMedPubMedCentral

88.

Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al (2006) 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205CrossRef

89.

Georges Q, Azoulay E, Mokart D, Soares M, Jeon K, Oeyen S et al (2018) Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data. Critical Care 22(1):326. https://doi.org/10.1186/s13054-018-2076-zCrossRefPubMedPubMedCentral

90.

Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014(10):Cd003039. https://doi.org/10.1002/14651858.CD003039.pub2.

91.

Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23(18):4198–4214. https://doi.org/10.1200/JCO.2005.05.645CrossRefPubMed

92.

Hu W, Sung T, Jessen BA, Thibault S, Finkelstein MB, Khan NK et al (2016) Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clinical Cancer Research : an official Journal of the American Association for Cancer Research 22(8):2000–2008. https://doi.org/10.1158/1078-0432.Ccr-15-1421CrossRef

93.

Spring LM, Zangardi ML, Moy B, Bardia A (2017) Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. The Oncologist 22(9):1039–1048. https://doi.org/10.1634/theoncologist.2017-0142CrossRefPubMedPubMedCentral

94.

Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ et al (2015) R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 125(9):1403–1410. https://doi.org/10.1182/blood-2014-10-604561CrossRefPubMedPubMedCentral

95.

Wesolowski R, Peereboom D, Weiss P, Elson P, Thomas BG (2010) Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies. Invest New Drugs 28(4):502–508. https://doi.org/10.1007/s10637-009-9258-0CrossRefPubMed

96.

Frasci G, Comella P, D'Aiuto G, Budillon A, Barbarulo D, Thomas R et al (1998) Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat 49(1):13–26. https://doi.org/10.1023/a:1005945218155CrossRefPubMed

97.

Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB (1999) Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients. J Clin Oncol 17(5):1407. https://doi.org/10.1200/jco.1999.17.5.1407CrossRefPubMed

98.

Sun HL, Atenafu EG, Yeboah E, Reece DE, Trudel S, Kukreti V et al (2015) Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone. Leuk Lymphoma 56(2):407–414. https://doi.org/10.3109/10428194.2014.915544CrossRefPubMed

99.

Wierda WG, Tambaro FP (2020) How I manage CLL with venetoclax-based treatments. Blood. 135(17):1421–1427. https://doi.org/10.1182/blood.2019002841CrossRefPubMed

100.

Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M et al (2019) Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 380(23):2225–2236. https://doi.org/10.1056/NEJMoa1815281CrossRefPubMed

101.

Roschewski M, Longo DL, Wilson WH (2021) CAR T-cell therapy for large B-cell lymphoma — who, when, and how? N Engl J Med 386(7):692–696. https://doi.org/10.1056/NEJMe2118899CrossRefPubMed

102.

Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ et al (2020) Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv 4(15):3776–3787. https://doi.org/10.1182/bloodadvances.2020002509CrossRefPubMedPubMedCentral

103.

Taneja A, CAR-T-OPENIA JT (2021) Chimeric antigen receptor T-cell therapy-associated cytopenias. eJHaem 3(S1):32–38. https://doi.org/10.1002/jha2.350CrossRefPubMedPubMedCentral

104.

Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J et al (2019) Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54(10):1643–1650. https://doi.org/10.1038/s41409-019-0487-3CrossRefPubMed

105.

Galli E, Allain V, Di Blasi R, Bernard S, Vercellino L, Morin F et al (2020) G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma. Bone Marrow Transplant 55(12):2347–2349. https://doi.org/10.1038/s41409-020-01006-xCrossRefPubMed

106.

Hayden PJ, Roddie C, Bader P, Basak GW, Bonig H, Bonini C et al (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 33(3):259–275. https://doi.org/10.1016/j.annonc.2021.12.003CrossRefPubMed

107.

Petrelli F, Morelli AM, Luciani A, Ghidini A, Solinas C (2021) Risk of infection with immune checkpoint inhibitors: a systematic review and meta-analysis. Targ Oncol 16(5):553–568. https://doi.org/10.1007/s11523-021-00824-3CrossRef

Titel: Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)
verfasst von: Hartmut Link
Publikationsdatum: 24.06.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 9/2022
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-022-07103-5

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Current state and future opportunities in granulocyte colony-stimulating factor (G-CSF)

Excerpt

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2022

Implementation of prehabilitation in colorectal cancer surgery: qualitative research on how to strengthen facilitators and overcome barriers

“It’s a Tall Order but I’ll Try”: a qualitative study on Chinese nurses’ cognition and experience responding to cancer patients’ requests to hasten death

One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)

Preferences for oral nutritional supplement therapy among postoperative patients with gastric cancer: a discrete choice experiment

Primary care–based follow-up for prostate and kidney cancer survivors: a retrospective monocentric study

Risk factors for developing medication-related osteonecrosis of the jaw when preserving the tooth that can be a source of infection in cancer patients receiving high-dose antiresorptive agents: a retrospective study

Neu im Fachgebiet Onkologie

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Update Onkologie